Pancreas Cancer Clinical Trial
Official title:
Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine
- This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. - It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
- CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio. - Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites. - Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis. - This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05435053 -
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 | |
| Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT05501379 -
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
|
||
| Recruiting |
NCT04851106 -
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
|
||
| Enrolling by invitation |
NCT04466189 -
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
|
||
| Not yet recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT01411072 -
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
|
N/A | |
| Active, not recruiting |
NCT01448668 -
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
|
N/A | |
| Completed |
NCT01155882 -
Registry Study - Whipple at the Splenic Artery
|
||
| Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 |